Rubicon Research Limited (RUBICON)

Rubicon Research Limited is a pharmaceutical formulations company specializing in the research, development, and manufacturing of innovative drug products. Its core focus is on developing specialty pharmaceutical products and drug-device combination solutions, with a robust portfolio that targets regulated markets, notably the United States and Canada. As of March 2024, Rubicon Research offered 55 commercialized products in the US across a variety of dosage forms, including oral tablets, capsules, solutions, suspensions, ophthalmic drops, and injectables. The company leverages proprietary drug delivery technologies backed by numerous patents, enabling it to address complex healthcare needs and differentiate within the competitive pharmaceuticals sector. With a strong emphasis on research and development, Rubicon Research operates US FDA-inspected R&D facilities in both India and Canada and maintains multiple manufacturing plants accredited by international regulatory agencies. The company is also active in mergers and acquisitions to expand its operational footprint, as seen in its recent acquisition of manufacturing assets from established peers. Rubicon Research Limited plays a significant role in advancing pharmaceutical technology and enhancing global healthcare delivery through its innovation-driven approach and regulatory expertise.